- Home
- NXGL vs ADVB Comparison
NXGL vs ADVB Comparison
Compare NXGL & ADVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXGL
- ADVB
- Stock Information
- Founded
- NXGL 1997
- ADVB 2014
- Country
- NXGL United States
- ADVB United States
- Employees
- NXGL N/A
- ADVB N/A
- Industry
- NXGL Medical/Dental Instruments
- ADVB Medical Specialities
- Sector
- NXGL Health Care
- ADVB Health Care
- Exchange
- NXGL Nasdaq
- ADVB Nasdaq
- Market Cap
- NXGL 19.7M
- ADVB 20.8M
- IPO Year
- NXGL 2021
- ADVB 2025
- Fundamental
- Price
- NXGL $2.36
- ADVB $0.50
- Analyst Decision
- NXGL
- ADVB
- Analyst Count
- NXGL 0
- ADVB 0
- Target Price
- NXGL N/A
- ADVB N/A
- AVG Volume (30 Days)
- NXGL 35.9K
- ADVB 259.9K
- Earning Date
- NXGL 08-13-2025
- ADVB 08-03-2025
- Dividend Yield
- NXGL N/A
- ADVB N/A
- EPS Growth
- NXGL N/A
- ADVB N/A
- EPS
- NXGL N/A
- ADVB N/A
- Revenue
- NXGL $10,228,000.00
- ADVB N/A
- Revenue This Year
- NXGL $52.35
- ADVB N/A
- Revenue Next Year
- NXGL $42.38
- ADVB N/A
- P/E Ratio
- NXGL N/A
- ADVB N/A
- Revenue Growth
- NXGL 116.01
- ADVB N/A
- 52 Week Low
- NXGL $2.10
- ADVB $0.46
- 52 Week High
- NXGL $5.10
- ADVB $4.10
- Technical
- Relative Strength Index (RSI)
- NXGL 42.79
- ADVB N/A
- Support Level
- NXGL $2.26
- ADVB N/A
- Resistance Level
- NXGL $2.58
- ADVB N/A
- Average True Range (ATR)
- NXGL 0.17
- ADVB 0.00
- MACD
- NXGL -0.03
- ADVB 0.00
- Stochastic Oscillator
- NXGL 18.25
- ADVB 0.00
About NXGL NexGel Inc
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.
About ADVB Advanced Biomed Inc. Common Stock
Advanced Biomed Inc operates through its subsidiaries that are responsible for the main operation and the design and development of the company's primary technologies and products. It has been focusing on the integration of multiple interdisciplinary technologies and established its microfluidic technology platform. Utilizing the physical and molecular biological characteristics of tumor cells, the company has developed various advanced and original research through the joint application of semiconductor technology and biotechnology. devices, A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.